Vasopressin

The earlier profile describes the nine-residue arginine vasopressin sequence shown above. A disulfide bridge joins the sulfur atoms of cysteine residues 1 and 6. The intended ring and terminal amide are parts of the molecular identity.

Vasopressin has FDA-approved drug products in specific forms. Approval belongs to those products and their authorised manufacturing and labelling, not to any research material carrying the same compound name.

The described Fmoc (a temporary chemical protecting group) route builds the protected linear chain on an amide-forming support. Cleavage releases the chain and removes side-chain protection. The manufacturing record needs to distinguish this linear intermediate from the closed product.

Oxidation then forms the disulfide bond. The earlier account compares air oxidation with alternative oxidation methods. Conditions affect the balance between the intended ring, dimers and other by-products, so closure needs analytical confirmation rather than an assumed completion time.

The older route uses primary reversed-phase separation and a later polishing step to remove incomplete chains, oxidation products, dimers and residues. Fraction identity and purity are both relevant to deciding what enters the pool.

Method development needs to show that the intended cyclic product is resolved from the species of concern. Column loading, solvent gradient and collection windows are linked choices. The inherited numerical examples do not establish a validated separation.

The earlier panel combines HPLC, mass spectrometry and amino acid analysis. Mass helps confirm the expected form, while composition and related-substance testing add information that a mass result alone cannot supply. Peptide content corrects for non-peptide material.

Water, residual solvents, elemental impurities, endotoxin and any sterility claim require separate results. A chromatogram should identify the method and its ability to separate relevant impurities. A generic passing purity result is not the complete release record.

The old account highlights oxidation around tyrosine and sulfur-containing residues, alongside other chemical changes under stress. Stability studies need methods that distinguish those products from the intended ring. Temperature, light and the container influence the study design.

Powder storage, shipping and monitoring remain manufacturing topics. A finished drug product’s handling requirements belong to its own authorised instructions and cannot be transferred to research material.

The manufacturing record should trace the linear intermediate, oxidation step, selected purification fractions and final identity results. Raw-material lots, calibration, deviations and quality approval connect the record to a released batch. Scale-up needs evidence for mixing and separation, with changes assessed through the quality system.

The original citations below are retained, including general FDA and ICH manufacturing guidance. They provide documentation context, not approval of research supply. The final certificate should identify the exact molecular form and the batch actually tested.

Vasopressin tables retain the earlier manufacturing examples. No Vasopressin table here validates an operating procedure, release limit or supplier result. The Vasopressin examples have no supporting batch raw data; use them to identify document fields, not to infer measured performance.

Vasopressin source links are retained below. These references give context for Vasopressin manufacturing; they do not validate the numerical examples. Duplicate Vasopressin source links retain the citation record.

1. Chan, W. C., & White, P. D. (Eds.). (2000). Fmoc Solid Phase Peptide Synthesis: A Practical Approach. Oxford University Press. https://doi.org/10.1093/oso/9780199637256.001.0001
2. Moroder, L., & Musiol, H. J. (2017). Insulin—from its discovery to the industrial synthesis of modern insulin analogues. Angewandte Chemie International Edition, 56(36), 10656-10669. https://doi.org/10.1002/anie.201702493
3. Bouchard, M., Zurdo, J., Nettleton, E. J., Dobson, C. M., & Robinson, C. V. (2000). Formation of insulin amyloid fibrils followed by FTIR simultaneously with CD and electron microscopy. Protein Science, 9(10), 1960-1967. https://doi.org/10.1110/ps.9.10.1960
4. Manning, M. C., Patel, K., & Borchardt, R. T. (1989). Stability of protein pharmaceuticals. Pharmaceutical Research, 6(11), 903-918. https://doi.org/10.1023/A:1015929109894
5. ICH Q7. (2000). Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. https://www.ich.org/page/quality-guidelines
6. Collins, J. M., Porter, K. A., Singh, S. K., & Vanier, G. S. (2014). High-efficiency solid phase peptide synthesis (HE-SPPS). Organic Letters, 16(3), 940-943. https://doi.org/10.1021/ol4036825
7. Behrendt, R., White, P., & Offer, J. (2016). Advances in Fmoc solid-phase peptide synthesis. Journal of Peptide Science, 22(1), 4-27. https://doi.org/10.1002/psc.2836
8. Coin, I., Beyermann, M., & Bienert, M. (2007). Solid-phase peptide synthesis: from standard procedures to the synthesis of difficult sequences. Nature Protocols, 2(12), 3247-3256. https://doi.org/10.1038/nprot.2007.454
9. Amblard, M., Fehrentz, J. A., Martinez, J., & Subra, G. (2006). Methods and protocols of modern solid phase peptide synthesis. Molecular Biotechnology, 33(3), 239-254. https://doi.org/10.1385/MB:33:3:239
10. Henninot, A., Collins, J. C., & Nuss, J. M. (2018). The current state of peptide drug discovery: Back to the future? Journal of Medicinal Chemistry, 61(4), 1382-1414. https://doi.org/10.1021/acs.jmedchem.7b00318